anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Using rhinovirus strain 16 (RV-16) for inoculation, this study is designed to examine mechanisms of the asthmatic response to RV in the atopic host. In keeping with this, the primary objective of this investigation will be to test the hypothesis that mild asthmatics enrolled in this study will experience significantly increased lower respiratory tract symptoms over the first 4 days after experimental inoculation with RV-16 than non-allergic, non-asthmatic controls (as shown in our previous studies). It is anticipated that the results will serve to guide the development of new treatments to prevent asthma attacks provoked by RV. This will be a 5 week longitudinal study of 18 young allergic adults with mild asthma and 18 non-asthmatic controls who will be evaluated for 1 week to establish baseline symptoms and lung function, followed by an inoculation with rhinovirus (strain-16) and subsequent clinical and laboratory (mechanistic) monitoring for an additional 4 weeks. To participate in this study, subjects must live within 90 minutes by car from the University of Virginia.

Note: This study has been reviewed and is being monitored for safety by the NIH/NIAID Safety Monitoring Committee and by teh University of Virginia IRB (#12673). The virus pool used for inoculation has been produced under GMP conditions and is approved for this research by the FDA.
We engaged with referred OUD patients at the time of their initial visit to the clinic. Interested patients were informed about the study in a private room, and if eligible, were consented and randomized to condition. Randomization occurred in blocks of 4. At the next physician visit, participants engaged in their first intervention activities (either CM or BSM). This was repeated for the following 3 physician visits.

CM. Contingency Management (CM). The CM intervention provided participants with a gift card at each of the first 4 follow up physician visits to the clinic where the participant's urine showed evidence of buprenorphine use. The strategy for CM rewards was based upon Petry's "fishbowl" draw, where variable values of gift cards were available for draw at each positive buprenorphine urine toxicology result. For the current study, which was conducted when COVID safety requirements were still high, a computerized "picker wheel" was used rather than an actual fishbowl to reduce possible viral transmission. Participants watched the wheel spin and told the interventionist when to stop the spin, at which time the value of the gift card was displayed. The picker wheel was programmed to include a 60% chance of a $25 gift card, a 20% chance of a $50 gift card, and a 20% chance of a $100 gift card. The average (expected) value of gift cards at this rate was $45 (or $180 total across 16 weeks, well below the typical range used in similar work).

BSM. Brief Motivational Interviewing plus Substance Free Activities Session plus Mindfulness (BSM). The BSM intervention included the following topics: (1) Short and Long-Term Goals: Identifying goals (e.g., What are your goals for this month...for the next 5 years?), requirements needed to achieve these goals (e.g., What would you need to do to achieve those goals?) and the potential role of relapse in jeopardizing these goals; (2) Personalized Feedback on Recent Time Allocation: (e.g., time spent with family, work, education/hobbies/creative activities, exercise/time in nature/self-care, watching tv/surfing the internet, religious or spiritual activities, recovery and nonrecovery activities; along with open ended questions asking about the extent to which their recent time allocation is consistent with their goals and values; (3) Episodic Future Thinking: An experiential intervention that prompts individuals to describe personal, emotional, and situational details of a valued future outcome that they desire; (4) Substance Free Activities: Based upon named hobbies and interests, participants were offered a personalized list of locally available substance-free activities developed by the interventionist; (5) Stop Observe Breathe Expand Respond (SOBER) Breathing Space: This exercise is intended to bring awareness to one's experiences without judgment. This technique includes the following steps: Stop or Slow down. Observe what is happening. Bring attention to Breathing. Expand awareness to the whole body. Respond mindfully, with awareness.
A method, apparatus, and computer program product is provided for tracking state data of objects during a session, and saving the data to a database. The tracking may be performed by a reusable set of computer program code accessible by a plurality of user interface applications. Temporary data may be stored as insert objects, update objects, and delete objects and maintained during a session of a user interface application. The temporary data may be updated as additional data is manipulated by the user interface application, but does not need to be tracked by the user interface application. The user interface application indicates if data is to be deleted, or is current (e.g., new or modified). Upon completion of the session, calls are made to update the database based on the temporary data.
The invention discloses a medicine for treating oculopathy. The medicine comprises the following active pharmaceutical ingredients in parts by weight: 12-17 parts of cassia seed, 12-17 parts of stem of noble dendrobium, 10-15 parts of climbing groundsel herb, 8-13 parts of chrysanthemum, 8-13 parts of feather cockscomb seed and 1-3 parts of borneol. The medicine is obtained by weighing the active pharmaceutical ingredients according to the parts by weight, washing, drying and sterilizing, soaking and decocting the active pharmaceutical ingredients, filtering the decoction, cooling the filtrate and re-sterilizing the filtrate. The medicine provided by the invention has the characteristics of quickness in effect taking, good curative effects and no toxic or side effects. The medicine is clinically used by totally 836 patients and the average cure rate is 91.5%. The medicine is convenient and fast to use.
This study consists of dose escalation and dose expansion in China. Subjects who fulfil all the inclusion criteria and none of the exclusion criteria will be enrolled and receive treatment with Sugemalimab, Etoposide/Cisplatin Chemotherapy and Olaparib for 4 cycles with LDRT in the first cycle. Sugemalimab in combination with olaparib will be administered for maintenance therapy after 4 cycles. Sugemalimab will be administered at a dose of 1200 mg every 3 weeks (Q3W) in the first day of every cycle. The LDRT deals with primary tumour in a 15 Gy of 5 fractions over five days, starting from day 1 in the first cycle. Dose of olaparib will identify by assessed recommended dose for expansion (RDE) in dose escalation stage.A dose expansion stage will be conducted after dose escalation. The primary endpoint is safety.
Although the number of gastric cancers in elderly is increasing with the aging population, the indications of surgical treatment depend on the individual cases and the decisions of doctors. We investigated the outcomes of gastrectomy in elderly patients aged 85 years and older who underwent surgery at our hospital. From 2014 to 2022, 72 cases of gastrectomy were performed in the elderly. The approaches were laparotomy in 28 cases, laparoscopic in 42, and robot-assisted in 2. There were 57 cases of distal gastrectomy, 7 cases of proximal gastrectomy, and 8 cases of total gastrectomy. The median operation time was 200 minutes, and the postoperative hospital stay was 14 days. There were 14 cases of complications of Grade Ⅱ or higher according to the Clavien-Dindo classification. Although intra-abdominal complications were not many, respiratory and circulatory complications were occasionally observed. The median follow-up period was 14.6 months, there were 10 deaths from other diseases. Risk factors for death from other diseases were laparotomy, postoperative complications, and outcomes other than discharging home. Although gastrectomy may be performed safely even in the elderly, it is important to pay attention to the patients' conditions particular to the elderly and to plan the surgery accordingly.
PURPOSE: An adhesive pad radiating electromagnetic wave is provided to remove fat by attaching the adhesive pad to a portion of the human body. CONSTITUTION: An adhesive pad radiating electromagnetic wave comprises a nutrition pad, an electromagnetic wave radiating pad(20), and a cylindrical cell(31). In the nutrition pad, drugs or nutrient components are attached. The electromagnetic wave radiation pad is attached on the top of the nutrition pad. The radiation pad is integrally combined with a film antenna(21), a frequency oscillator(22), and an LED(40). The film antenna radiates electromagnetic wave and removes wrinkles by relieving the muscle of the facial area or decomposes fat of other portions of the human body. The cylindrical cell is combined with a battery socket(30).
A pharmaceutical composition containing an anti-proliferative compound, named Tecomaphorbide, which is identified and isolated from  Tecoma  plants (e.g.  Tecoma stans ). The pharmaceutical composition may contain a derivative and/or a salt of Tecomaphorbide. A process of obtaining Tecomaphorbide from  Tecoma  plants is specified. A method of treating cancer (e.g. leukemia, lymphoma, breast, colon, and prostate cancer) with the pharmaceutical composition is also provided.
Participants in this arm will receive doses of ZV (from 1.5 mg/Kg up to 2.5 mg/Kg) plus Rituximab 375 mg/m\^2, Bendamustine 90 mg/m\^2 (BR) given intravenously on Day 1 and 2 of repeated 21-day cycles. Treatment will continue for up to 6 cycles.
Chronic kidney disease - mineral and bone disease (CKD-MBD) is a disorder of bone and mineral metabolism in patients with CKD. When kidney function is poor, levels of vitamin D, phosphate and parathyroid hormone become abnormal and patients are at risk for bone disease and fractures (renal osteodystrophy) and the deposition of calcium in blood vessels and muscles. CKD-MBD increases the risk of fractures, heart attacks, strokes, and death. Treatment of CKD-MBD is focused on lowering levels of parathyroid hormone (PTH) by giving vitamin D and lowering levels of phosphorous by giving phosphate binders. In patients with end stage kidney disease (ESKD), target levels of PTH recommended by the Kidney Disease Improving Global Outcomes (KDIGO) guidelines are in the range of 2-9 times the upper limit of normal (ULN) for the PTH assay. In many cases, in patients with long-standing ESKD, the parathyroid gland may no longer respond to treatment with vitamin D and phosphate lowering. In these cases, treatment with a calcimimetic, a medicine that increases the sensitivity of the parathyroid gland to serum levels of calcium, can restore PTH levels to goal.
Most countries in sub-Saharan Africa have adopted differentiated care models for people living with HIV (PLWH), including Rwanda. Current Rwandan HIV guidelines classify newly-diagnosed PLWH as "unstable", requiring monthly visits to the health facility. Before they can advance to being "stable" patients, with spaced-out appointments that allow them to visit the health facility every three months, they must be on antiretroviral therapy (ART) for 18 months and virally suppressed on two consecutive measurements. Patients face multiple barriers to attending frequent appointments including structural issues (such as distance to the health facility, transportation cost, long waiting times) and facing stigma while traveling to and while at the health facility. Reducing the time newly-diagnosed PLWH spend in the "unstable" category could potentially decrease the burden on patients and the health facility and potentially decrease the costs of frequent appointments. The investigators therefore propose a pilot study to examine the effect of reducing the time from ART initiation to advancement to the "stable" category from 18 to 6 months. The investigators will enroll 90 patients: 30 will be randomized to 6-month advancement to spaced out appointments after 1 viral load is measured (at 5 months after enrollment in ART care) ("Early 1"); 30 will be randomized to 6-month advancement to spaced-out appointments after 2 viral loads are measured (at 3- and 5-months after enrollment in ART care) ("Early 2"); and 30 will be randomized to continue in usual care with monthly visits ("Usual care"). The investigators will compare study arms with respect to viral suppression at 12 months (primary outcome) and appointment/pharmacy adherence (secondary outcome). The investigators hypothesize that reducing the time to the "stable" category with spaced out appointments will be feasible, acceptable, not inferior to 18 months with respect to viral suppression or adherence, and will be cost-effective.
The investigators propose to randomize overweight or obese, African American postpartum WIC participants (n=300) to either usual care (UC) or a community-based obesity treatment (PP) arm. Recruitment will occur in 6 of Philadelphia Women Infants Children's (WIC) clinic sites in the early postpartum period (≤ 6 months after birth). Once enrolled, participants will complete surveys and baseline assessments of their weight, waist circumference, blood pressure, and height at The Center for Obesity Research and Education (CORE). Participants will also have a fasting blood sample taken. Study staff will administer a number of questionnaires assessing demographics, psychosocial factors, contextual factors, and behavioral targets via questionnaires prior to randomization. Participants will then be randomized to the 12-month postpartum weight loss intervention (PP) or usual care (UC). Additional assessments will be conducted at 6 and 12 months post baseline. The PP arm includes expanded obesogenic behavior change goals, tailored skills training materials, interactive self-monitoring text messages, video testimonials, and interpersonal counseling support through health coach calls and Facebook. Data will be analyzed using an intent-to-treat (ITT) approach where subjects are analyzed according to their treatment assignment at randomization, regardless of level of engagement. The primary outcome is weight loss at 12 months. If successful, the expected results could provide a sustainable, low-cost, postpartum weight loss intervention model for widespread dissemination to reduce disparities in obesity and cardiometabolic comorbidities.
New concept was developed for formation of human- and environmental- friendly material able to provide antibacterial activity. This material is composed of bioceramic (hydroxyapatite), metallic (gold) and organic part containing amino and thiol groups (amino acids) in the form of composite. Bioceramic part of this material is templating agent applied as a controller of growth and stability of metallic nanoparticles particle. These metallic nanoparticles have functionalized surface and they are centers of antibacterial activity of composites. Efficacy of antibacterial activity of these materials depends on selection of surface functionalization providing activity against both Gram-positive and Gram-negative bacteria. For developed materials this activity is much stronger compare to HAp/Ag composite which shows ability for their use as more favorable replacement of toxic silver. Materials were synthesized using sonochemical method, which has been developed as a novel, "green" approach for their formation.
American workers spend 70-80% of their time at work sitting at a desk, working on a computer, talking on a telephone, and sitting in meetings. Traditional approaches to increase MVPA in the workplace may not be sustainable as they require deliberate and dedicated time away from work, and may be perceived as harmful to productivity. Sedentary behavior interventions, in contrast, do not interfere with daily tasks and productivity and require small but cumulative changes in posture and LPA throughout the workday.

Sedentary behavior interventions in the worksite, including those conducted by our team, have shown promising effects. Studies that have used multi-level approaches targeting individual, social, and environmental factors have been most effective. The most robust environmental support has been the use of sit-stand workstations, providing distinct opportunities for workers to reduce sitting while maintaining productivity. However, treadmill desks may provide an even greater opportunity to both reduce sitting and increase LPA during the workday. Thus, a pilot study is required to test the efficacy of this approach to reduce sitting and increase LPA in the workplace.
The numerical expressions were presented in a negative way: e.g. treatment was unsuccessful for 6 out of 10 persons.
PROBLEM TO BE SOLVED: To obtain the subject medicine showing high treatment effects against itching, ache and inflammations of the skin by including a local anesthetic, vitamin E and squalene. SOLUTION: This medicine contains 0.01 to 30 wt.% of a local anesthetic, 1.0 to 99.8 wt.% of vitamin E and 0.1 to 98 wt.% of squalene. It may be further incorporated with at least one type of percutaneous absorption accelerator selected from the group consisting of N-acylsarcosine (salt), a higher fatty acid ester as the product of the reaction between a 10-18C higher fatty acid and 1-20C alcohol, 2-10C dicarboxylic acid (salt), hydroxycarboxylic acid ester as the product of the reaction between a 3-6C hydroxycarboxylic acid and 1-20C alcohol, and aliphatic ethanol amide. The medicine is administered to the affected part at 0.1 to 10 g a day in several times. Presence of vitamin E and squalene can reduce content of the local anesthetic required for sufficient treatment effects.  As a result, the medicine shows high and safe treatment effects, while controlling the side effects of the anesthetic, e.g. hives, edema and anthema.
PURPOSE: To report a case of primary vitreoretinal lymphoma (VRL) presenting as diffuse large b-cell lymphoma 19 years after initial systemic follicular lymphoma.
METHOD: A case report.
RESULTS: An 81-year-old male patient presented with a 1-month history of floaters and blurry vision in the left eye. He had a history of follicular non-Hodgkin lymphoma treated with systemic chemotherapy in 2002 and prostate cancer treated surgically in 2004. Ophthalmic examination revealed vitritis, retinal whitening, perivascular sheathing, and a vascularized cream-colored retinal mass in the superonasal periphery of the left eye. Diagnostic vitrectomy with retina and vitreous biopsies demonstrated diffuse large b-cell lymphoma. Positron emission tomography/computed tomography confirmed the isolated lesion in the left eye without systemic involvement. Treatment with systemic and intraocular chemotherapy was planned.
CONCLUSION: To the best of our knowledge, this is the first reported case of primary vitreoretinal lymphoma of diffuse large b-cell lymphoma transformed from follicular lymphoma. Intravitreal and systemic chemotherapy, including rituximab, should be considered in the management of patients with transformed vitreoretinal lymphoma.
In experimental groups, the dosage of dicycloplatin (TP21) was based on the body surface area (550 mg/m2) according to previous research. If grade III or above myelosuppression was observed, an adjusted dose of 450 mg/m2 was then considered, or the patient was removed from the group at the investigator's discretion.The volume ratio of lipiodol to dicycloplatin aqueous solution was 1:1.The volume of lipiodol used was calculated by the size and vascularity of the tumor, within 20 mL. Standardized gelatin sponge particles of 150-350 μm or 350-560 μm in diameter were injected following embolization with ethiodized oil-chemoembolic emulsion.
The Nature Coach intervention, developed in a prior study (NCT04146025), will be delivered to people in their homes. Participants will live in the blocks immediately surrounding the study vacant lots randomized to this arm. The lots in this arm receive no intervention.
The invention discloses a traditional Chinese medicine composition for treating sciatica and a preparation method and application thereof. The traditional Chinese medicine composition is prepared from, by weight, 3-8 parts of dysosma versipellis (Hance) M. Cheng ex Ying, 11-20 parts of dewberryleaf cinquefoil roots and 8-15 parts of smilax scobinicaulis C.H. Wright. The preparation method includes the steps that the dewberryleaf cinquefoil roots are dried, smashed and soaked in ethyl alcohol, and a dewberryleaf cinquefoil root soak solution is obtained; the dysosma versipellis (Hance) M. Cheng ex Ying and the smilax scobinicaulis C.H. Wright are put into a decocting pot, water is added, the mixture is decocted through slow fire, then the dewberryleaf cinquefoil root soak solution is added, the mixture continues to be decocted through slow fire, water is added again, the mixture continues to be decocted through slow fire, the mixture is filtrated, and filtrate is obtained; the filtrate is concentrated and dried, and the traditional Chinese medicine composition for treating sciatica is obtained. Under the scientific compatibility of the dysosma versipellis (Hance) M. Cheng ex Ying, the dewberryleaf cinquefoil roots and the smilax scobinicaulis C.H. Wright, the traditional Chinese medicine composition is significant in treatment effect, low in recurrence rate after recovery, safe and effective when used for treating sciatica, and no obvious adverse reaction is found.
The aim of the study is to systematically investigate the effects of a diet enriched with legumes in the dietary pattern approach (Planetary Health Diet) compared to a control diet low in legumes in older people with a risk phenotype for cardiovascular and neurodegenerative diseases. For this purpose, a controlled, six-week nutritional intervention study will be carried out in a parallel design. A total of 100 subjects (aged 50 - 75 years) will be randomly assigned to one of two intervention groups: i) a legume-rich diet based on the Planetary Health Diet, with a focus on plant protein, ii) a diet based on the Western dietary pattern including animal protein sources (= control diet). The target variables include parameters of lipid, glucose and insulin metabolism as well as biomarkers of inflammation and endothelial activation, proteomics and neurodegeneration markers. Furthermore, pulse wave velocity is measured to assess vascular function and neuropsychological target variables (e.g. hunger, satiety) are recorded using questionnaires. The subjects come to the study center for examination before the start of the intervention (visit 1), after three weeks (mid-intervention, visit 2) and after six weeks (end of intervention, visit 3).
Patients will be enrolled in the order of confirmation of eligibility. Dose cohorts will be filled sequentially with a minimum of 3 patients. Once assigned to a dose cohort, each patient will continue to be treated at the same dose level throughout the course of the study.
Hu3S193 was administered weekly for 8 consecutive weeks. The antibody was diluted in physiologic saline containing 5% human serum albumin and infused intravenously at a maximum rate of 100 mg/hour. If patients were stable or responding, they were eligible to receive 8-week maintenance cycles of hu3S193 at 10 mg/m2 starting in week 10 and continuing until progression.
Women in the standard of care arm (n=375) will receive facility-based PrEP and monthly HIV testing in pregnancy and quarterly in postpartum. PrEP prescriptions and HIV testing will be provided according to the national PrEP guidelines. The women will be followed through 6m postpartum for the first randomization and through 15m with the standard of care for the second randomization.